<DOC>
	<DOCNO>NCT02358473</DOCNO>
	<brief_summary>The purpose study evaluate safety mogamulizumab combination docetaxel adult subject previously treat locally advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Study Mogamulizumab + Docetaxel Subjects With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm Stage IIIB IV advance metastatic NSCLC measurable neoplastic disease . Sputum cytology alone consider acceptable method diagnosis ; Prior therapy must meet following criterion : 1 . Subject experienced disease progression unacceptable toxicity/intolerance receive least 1 systemic platinumcontaining regimen ; 2 . Subject tumor nonsquamous histology must test epidermal growth factor receptor ( EGFR ) mutation anaplastic lymphoma kinase ( ALK ) rearrangement . Subject EGFR activate mutation ALK rearrangement must experience disease progression unacceptable toxicity/intolerance receive least one EGFR tyrosine kinase inhibitor ALK inhibitor ; 3 . Subject receive PD1/PDL1 blockade inform result relevant positive Phase 3 trial agent . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 baseline ; Minimum life expectancy 3 month ; Agrees use medically effective method contraception . Male subject woman childbearing potential ( WOCBP ) must agree use effective contraception , e.g. , oral contraceptive , double barrier method ( condom plus spermicide diaphragm plus spermicide ) , practice true abstinence sexual intercourse study 3 month last dose . Women childbearing potential include female subject experience menarche undergone surgical sterilization postmenopausal ( define amenorrhea ≥ 12 consecutive month without alternative medical cause ) ; WOCBP must negative serum pregnancy test within 7 day prior receive investigational product negative urine pregnancy test Day 1 Cycle ; Recovered ( i.e. , Grade ≤ 1 baseline level ) effect recent surgery , radiotherapy , chemotherapy , hormonal therapy , therapy cancer ( exception alopecia resolution require peripheral neuropathy must resolve Grade ≤ 1 subject receive prior taxanebased chemotherapy ) ; Adequate organ function define : 1 . Total bilirubin ≤ upper limit normal ( ULN ) ; 2 . Hemoglobin ( Hgb ) ≥ 9.0 g/dL ; 3 . Serum creatinine ( sCr ) ≤ 1.5 x ULN ; 4 . Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 ; 5 . Platelets ≥ 100 × 109/L ; Sufficient archive tumor sample ( take within 6 month prior treatment may submit ) available PD assessment , willingness undergo pretreatment core needle biopsy , preferably primary tumor , order obtain tissue ; Willing able undergo postdose core needle biopsy . Prior treatment docetaxel mogamulizumab ; Requires administration prohibit medication treatment ; Has significant uncontrolled intercurrent illness include , limited : 1 . Ongoing active infection require antibiotic ; 2 . Clinically significant cardiac disease ( class III , IV New York Heart Association classification ; unstable angina pectoris , myocardial infarction within 6 month post angioplasty stenting within 6 month ; clinically significant cardiac arrhythmia , uncontrolled hypertension ( i.e. , systolic blood pressure &gt; 150 mm Hg , diastolic blood pressure &gt; 90 mmHg ) despite antihypertensive medication ; 3 . Uncontrolled diabetes , active liver disease , poorly control chronic obstructive pulmonary disease , serious nonhealing wound , ulcer , fracture ; 4 . Known test positive human immunodeficiency virus , hepatitis B , hepatitis C 5 . Active know autoimmune disease exception autoimmune thyroiditis , vitiligo , alopecia ; 6 . Pleural effusion require repetitive drainage , i.e. , indwell catheter 2 thoracenteses 6 week first dose mogamulizumab ; Received monoclonal antibody ( reason ) , chemotherapy , surgery , investigational therapy , radiotherapy within 14 day first dose mogamulizumab ; Received live , attenuated vaccine within 28 day prior first dose mogamulizumab ; Use immunosuppressive medication within 14 day first dose mogamulizumab . Note : Inhaled , intranasal , intraarticular , topical corticosteroid allow . Nonimmunosuppresive dos systemic steroid adrenal replacement contrast allergy allow ; ; Any history sign central nervous system metastasis ; Any history sign pulmonary lymphangitic spread ; Experienced Grade 3 high hypersensitivity reaction monoclonal antibody therapeutic protein , reaction could control prevented subsequent infusion standard therapy antihistamine , 5hydroxytryptamine ( 5HT3 ) receptor antagonist , corticosteroid ; The subject history severe hypersensitivity reaction drug formulate polysorbate 80 ; History second primary cancer within past 5 year , exception : 1 . Curatively resect nonmelanomatous skin cancer ; 2 . Curatively treated cervical intraepithelial neoplasia prostate carcinoma current prostate specific antigen ( PSA ) &lt; 0.01 ng/mL ; 3 . Curatively treated ductal carcinoma situ breast ; The subject pregnant breastfeeding . The subject aspartate aminotransferase and/or alanine aminotransferase &gt; 1.5 × ULN , concomitant alkaline phosphatase &gt; 2.5 × ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nonsmall Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
	<keyword>Carcinoma , Non-Small Cell Lung</keyword>
	<keyword>KW-0761</keyword>
	<keyword>Mogamulizumab</keyword>
</DOC>